Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment.
Supporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment.
This study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery.
The long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively.
NR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.

Start Date01 May 2025

Sponsor / Collaborator-

NCT06567717

/ Not yet recruitingPhase 2IIT

Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Start Date01 Jan 2025

Sponsor / Collaborator

Cedars-Sinai Health System

NCT04614714

/ Not yet recruitingPhase 2/3IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

Start Date01 Dec 2024

Sponsor / Collaborator

University of California, Davis

100 Clinical Results associated with Nicotinamide riboside

100 Translational Medicine associated with Nicotinamide riboside

100 Patents (Medical) associated with Nicotinamide riboside

1,144

Literatures (Medical) associated with Nicotinamide riboside

01 Apr 2025·ESC Heart Failure

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

Review

Author: Song, Jia ; Liu, Xiaohong ; Zhang, Wei ; Yao, Shun ; Li, Shujuan ; Fang, Zhuyubing ; Lu, Junyan ; Raza, Umar

Abstract:

Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac amyloidosis, elevating susceptibility to chronic heart failure (HF) in the elderly. Age‐related cardiac dysfunction stems from prolonged exposure to genomic, epigenetic, oxidative, autophagic, inflammatory and regenerative stresses, along with the accumulation of senescent cells. Concurrently, age‐related structural and functional changes in the vascular system, attributed to endothelial dysfunction, arterial stiffness, impaired angiogenesis, oxidative stress and inflammation, impose additional strain on the heart. Dysregulated mechanosignalling and impaired nitric oxide signalling play critical roles in the age‐related vascular dysfunction associated with HF. Metabolic aging drives intricate shifts in glucose and lipid metabolism, leading to insulin resistance, mitochondrial dysfunction and lipid accumulation within cardiomyocytes. These alterations contribute to cardiac hypertrophy, fibrosis and impaired contractility, ultimately propelling HF. Systemic low‐grade chronic inflammation, in conjunction with the senescence‐associated secretory phenotype, aggravates cardiac dysfunction with age by promoting immune cell infiltration into the myocardium, fostering HF. This is further exacerbated by age‐related comorbidities like coronary artery disease (CAD), atherosclerosis, hypertension, obesity, diabetes and chronic kidney disease (CKD). CAD and atherosclerosis induce myocardial ischaemia and adverse remodelling, while hypertension contributes to cardiac hypertrophy and fibrosis. Obesity‐associated insulin resistance, inflammation and dyslipidaemia create a profibrotic cardiac environment, whereas diabetes‐related metabolic disturbances further impair cardiac function. CKD‐related fluid overload, electrolyte imbalances and uraemic toxins exacerbate HF through systemic inflammation and neurohormonal renin‐angiotensin‐aldosterone system (RAAS) activation. Recognizing aging as a modifiable process has opened avenues to target systemic aging in HF through both lifestyle interventions and therapeutics. Exercise, known for its antioxidant effects, can partly reverse pathological cardiac remodelling in the elderly by countering processes linked to age‐related chronic HF, such as mitochondrial dysfunction, inflammation, senescence and declining cardiomyocyte regeneration. Dietary interventions such as plant‐based and ketogenic diets, caloric restriction and macronutrient supplementation are instrumental in maintaining energy balance, reducing adiposity and addressing micronutrient and macronutrient imbalances associated with age‐related HF. Therapeutic advancements targeting systemic aging in HF are underway. Key approaches include senomorphics and senolytics to limit senescence, antioxidants targeting mitochondrial stress, anti‐inflammatory drugs like interleukin (IL)‐1β inhibitors, metabolic rejuvenators such as nicotinamide riboside, resveratrol and sirtuin (SIRT) activators and autophagy enhancers like metformin and sodium‐glucose cotransporter 2 (SGLT2) inhibitors, all of which offer potential for preserving cardiac function and alleviating the age‐related HF burden.

01 Apr 2025·BONE

The protection of nicotinamide riboside against diabetes mellitus-induced bone loss via OXPHOS

Article

Author: Dai, Shiyou ; Meng, Xiangyuan ; Yang, Xingxiang ; Gao, Tianlin ; Gong, Jianbao ; Zhang, Junwei ; Tian, Chunyan ; Xie, Chenqi ; Gao, Jie

Diabetes mellitus is a global disease that results in various complications, including diabetic osteoporosis. Prior studies have indicated a correlation between low levels of nicotinamide adenine dinucleotide (NAD⁺) and diabetes-related complications. Nicotinamide riboside (NR), a widely utilized precursor vitamin of NAD⁺, has been demonstrated to enhance age-related osteoporosis through the Sirt1/FOXO/β-catenin pathway in osteoblast progenitors. However, the impact of NR on bone health in diabetes mellitus remains unclear. In this study, we assessed the potential effects of NR on bone in diabetic mice. NR was administered to high-fat diet (HFD)/streptozotocin (STZ)-induced type 2 diabetic mice (T2DM), and various parameters, including metabolic indicators, bone quality, bone metabolic markers, and RNA sequences, were measured. Our findings confirmed that HFD/STZ-induced T2DM impaired bone microstructures, resulting in bone loss. NR effectively ameliorated insulin resistance, improved bone microarchitecture, and bone quality, reduced bone resorption, enhanced the Forkhead box O (FOXO) signaling pathway, mitigated the nuclear factor kappa B (NF-kB) signaling pathway, and ameliorated the disorder of the oxidative phosphorylation process (OXPHOS) in diabetic mice. In conclusion, NR demonstrated the capacity to alleviate T2DM-induced bone loss through the modulation of OXPHOS in type 2 diabetic mice. Our results underscore the potential of NR as a therapeutic target for addressing T2DM-related bone metabolism and associated diseases. Further cell-based studies under diabetic conditions, such as in vitro cultures of key cell types (e.g., osteoblasts and osteoclasts), are necessary to validate these findings.

04 Mar 2025·Journal of the American Heart Association

Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels

Article

Author: Habeichi, Nada J. ; Momken, Iman ; Mericskay, Mathias ; Amin, Ghadir ; Zouein, Fouad A. ; Ghali, Rana ; Diab, Reine ; Tannous, Cynthia ; Boitard, Solene ; Booz, George W.

Background:

Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adenine dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation, and in its oxidized form it is a substrate for multiple NAD + ‐dependent enzymes such as sirtuins and poly‐ADP ribose polymerases. Decreased cardiac NAD levels, along with a downregulation of NAMPT (nicotinamide phosphoribosyl transferase), have been reported following MI. A compensatory upregulation in NMRK (nicotinamide riboside kinase) 2, an NAD + biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD + , takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before.

Methods and Results:

MI was induced by ligating the left anterior descending coronary artery in 2‐month‐old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI‐induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post‐MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT‐mediated increase in renal NAD levels, notably in the distal tubules.

Conclusions:

Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.

News (Medical) associated with Nicotinamide riboside

04 Feb 2025

·www.prnewswire.com

NexGen Health Introduces Niagen Plus IV Therapy: Revolutionizing Cellular Health and Anti-Aging in Silicon Valley

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide riboside (NR). This innovative therapy complements NexGen Health's regenerative medicine offerings, setting a new standard for wellness in Silicon Valley. SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- NexGen Health, Silicon Valley's premier destination for cutting-edge regenerative wellness, is proud to announce the launch of Niagen Plus IV Therapy, an innovative treatment designed to enhance cellular health, boost energy, and combat the effects of aging. This groundbreaking therapy harnesses the power of nicotinamide riboside (NR), a key precursor to NAD+ (Nicotinamide Adenine Dinucleotide), combined with IV delivery for optimal absorption and faster results. The Science Behind Niagen Plus IV Therapy Continue Reading NexGen Health NAD+ is a vital coenzyme found in all living cells, responsible for energy production, DNA repair, and cellular regeneration. As people age, NAD+ levels naturally decline, leading to fatigue, cognitive decline, and other age-related conditions. Niagen Plus IV Therapy replenishes NAD+ levels by delivering nicotinamide riboside (NR) directly into the bloodstream, bypassing the digestive system to ensure maximum efficacy and rapid cellular uptake. "Our Niagen Plus IV Therapy is a game-changer for patients seeking to improve energy levels, optimize cognitive function, and support overall longevity," said Ilbra Petros, Director of NexGen Health." This treatment is perfect for anyone looking to combat the cellular effects of aging and enhance their vitality." Key Benefits of Niagen Plus IV Therapy Cellular Regeneration: Restores NAD+ levels to support healthier, more resilient cells. Enhanced Energy: Improves mitochondrial function to combat fatigue and sustain energy throughout the day. Cognitive Performance: Boosts brain health, improving focus, memory, and overall mental clarity. Anti-Aging Effects: Supports DNA repair, reduces oxidative stress, and promotes healthy aging. Synergistic Wellness: Complements other treatments offered at NexGen Health, such as NAD therapy, peptides, and IV nutrient infusions. A New Standard of Care in Silicon Valley Located in the heart of San Jose, NexGen Health is renowned for its personalized, concierge-level wellness services. With the addition of Niagen Plus IV Therapy, NexGen Health continues to lead the way in advanced regenerative medicine, offering residents of Silicon Valley and beyond an opportunity to optimize their health at the cellular level. "Niagen Plus IV Therapy represents the future of anti-aging and wellness," added Ilbra. "We are thrilled to bring this innovative treatment to the Bay Area, providing our patients with a scientifically-backed solution to improve their quality of life and unlock their full potential." About NexGen Health NexGen Health is a state-of-the-art wellness center located in San Jose, CA, specializing in advanced regenerative medicine and innovative health solutions. From NAD therapy and peptide treatments to IV nutrient infusions and comprehensive wellness consultations, NexGen Health offers cutting-edge services tailored to individual patient needs. As a leader in cellular health and anti-aging therapies, NexGen Health combines the latest advancements in medical science with concierge-level care to deliver exceptional results. Schedule Your Niagen Plus IV Therapy Consultation Today To learn more about Niagen Plus IV Therapy or schedule a consultation, visit NexGen Health online at or call (408) 400-2967. Media Contact: Ilbra Petros NexGen Health 408-400-2967 [email protected] SOURCE NexGen Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

22 Nov 2024

·www.drugs.com

Could a Vitamin Be Effective Treatment for COPD?

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD , Danish researchers report. "This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen , of the University of Copenhagen. Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal. The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo. After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%. "In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study." More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said. During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process. NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging . "As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking." As such, he said NAD may be a target for future research and treatment. Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Sep 2024

·www.businesswire.com

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Oligonucleotide

100 Deals associated with Nicotinamide riboside

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nicotinamide riboside	A11HA01	DB14933

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiotoxicity	Phase 2	Norway	ChromaDex, Inc.	16 Mar 2023
Heart Failure	Phase 2	Norway	ChromaDex, Inc.	16 Mar 2023
Myocardial injury	Phase 2	Norway	ChromaDex, Inc.	16 Mar 2023
Head and Neck Neoplasms	Phase 2	United States	ChromaDex, Inc.	08 Nov 2019
Metastatic breast cancer	Phase 2	United States	ChromaDex, Inc.	08 Nov 2019
Metastatic endometrial cancer	Phase 2	United States	ChromaDex, Inc.	08 Nov 2019
Peripheral Nervous System Diseases	Phase 2	United States	ChromaDex, Inc.	08 Nov 2019
Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	ChromaDex, Inc.	08 Nov 2019
Acute febrile illness	Phase 2	Norway	ChromaDex, Inc.	01 Oct 2019
Critical Illness	Phase 2	Norway	ChromaDex, Inc.	01 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	xyjorfwsvg(mudoxqpfye) = orkbnnkkle vbeqznvhlb (cbmrpmmluj, 7.84) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	xyjorfwsvg(mudoxqpfye) = odmtfzegyw vbeqznvhlb (cbmrpmmluj, 8.69) View more
NCT04990869 (Pubmed \| Nat Aging)	Not Applicable	Pulmonary Disease, Chronic Obstructive sputum interleukin-8 (IL-8)	40	Nicotinamide Riboside	zwufrobgjh(utboaghcev) = gyivzqraek igynxrbskl (oupycavmmh, -75.7 to -7.6)	Positive	15 Nov 2024
				Placebo	-
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	yucwkkppnf(hhxlxprlqi) = fvxyykrdvb wiotxyvwcu (zetsrkurgp )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
NCT03912220 (CTgov)	Phase 2	Small Fiber Neuropathy	45	Nicotinamide riboside (Nicotinamide Riboside)	mtegwpngin(nyvuhjmltf) = ztgtpfhnjp gpihkbsvlm (lcpzgtolns, phlmpyqshq - xfkwjqcpln) View more	-	06 Jun 2024
				Placebo Oral Tablet (Placebo)	mtegwpngin(nyvuhjmltf) = qqxoyhxgai gpihkbsvlm (lcpzgtolns, grbfhqhzhm - qxamyghoya) View more
NCT04112043 (CTgov)	Phase 1	Hypertension	147	Walking Exercise+Nicotinamide Riboside (NR) (NR Plus Walking Exercise)	lubunlxpry(dtzstejzeu) = cwdjwlnbbc lvyyflhozc (bstdbzrfge, ytjabqhwhk - mfaiwifkii) View more	-	06 Jun 2024
				Walking Exercise (Walking Exercise Plus Placebo)	lubunlxpry(dtzstejzeu) = rdhjrilvih lvyyflhozc (bstdbzrfge, ytqksosyye - hjiwajpswa) View more
ATS2024	Not Applicable	Sepsis	-	Nicotinamide Riboside (NR) 30 mg/kg	qvcxlzetjj(aldoxvmugg) = twcsohcyqw amjuavtxup (oldkbvigjl )	-	19 May 2024
				H2O control	qvcxlzetjj(aldoxvmugg) = uxqlhwpxhx amjuavtxup (oldkbvigjl )
NCT03151707 (CTgov)	Phase 4	-	11	Nicotinamide Riboside	sqvcaqztno(fhvuqtjoad) = tphfprpdbs jpvyjhvcam (velfpnhqkb, 0.025) View more	-	05 Mar 2024
NCT04818216 (NIRVANA, CTgov)	Phase 2	COVID-19 \| Acute Kidney Injury	28	Placebo (Placebo Group)	hrngapfxzl(sqqhzfvmts) = yqxngmgosc jdznkeqwrj (evoegvtkgy, 0.02) View more	-	26 Dec 2023
				Nicotinamide riboside (Nicotinamide Riboside Group)	hrngapfxzl(sqqhzfvmts) = roixaaodjs jdznkeqwrj (evoegvtkgy, .07) View more
Biospace Manual	Phase 1	Parkinson Disease	20	Niagen 3000 mg	xtsxbhrfcy(mygirzllwk) = High-dose NR was safe and well-tolerated with no related adverse events. euqjbkmryt (kmqrfjsnof ) View more	Positive	30 Nov 2023
				placebo
NCT02942888 (Pubmed)	Not Applicable	Mild cognitive disorder NAD+	-	Nicotinamide riboside (NR) 1 g/day	ltdwwtfcel(hcemfhydlt) = MoCA and other neurocognitive and psychometric metrics remained stable throughout the study qmpbtuzuxw (jclfqiazia ) View more	-	23 Nov 2023
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nicotinamide riboside

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation